本研究では、薬剤評価に用いるヒト培養細胞の遺伝子発現レベルをデータベース化し、癌細胞に高発現している機能性分子を予め探索するとともに、特にポストFDG製剤の中でも有力候補であるアミノ酸製剤を取り上げ、腫瘍で特異的に高発現が認められるアミノ酸トランスポータに高親和性を示す標識アミノ酸の集積機序を詳細に検討し、アミノ酸トランスポータ遺伝子発現と腫瘍集積性との相関からその設計戦略の妥当性を評価した。
While searching this research for the functional biomolecule used by the database for the gene expression level of the human cultured cells for evaluation of imaging probes, and it has high-expressed to the tumor cell beforehand, the amino acid derivatives are especially taken up also in a post-FDG candidate probe, and the accumulation mechanism of the labeled amino acids which shows high affinity to the amino acid transporters to which high revelation is specifically accepted by a tumor was examined in detail, and the validity of the design strategy was evaluated from correlation with amino acid transporter gene expression and tumor accumulation of the probes.
ヒト培養細胞の機能性分子発現解析に基づくポストFDG腫瘍診断薬の設計戦略の構築
.png)
ME-PR-KAWAI-K-kaken 2012-5p.pdf
(269.8KB)
